Delivering therapeutic levels of lysosomal enzymes across the blood-brain barrier (BBB) has been a pivotal issue in treating CNS storage diseases, including the mucopolysaccharidoses. An inherited deficiency of ␤-glucuronidase (GUS) causes mucopolysaccharidosis type VII that is characterized by increased systemic and CNS storage of glycosaminoglycans. We previously showed that the neonate uses the mannose 6-phosphate (M6P) receptor to transport phosphorylated GUS (P-GUS) across the BBB and that this transporter is lost with maturation. Induction of expression of this BBB transporter would make enzyme replacement therapy in the adult possible. Here, we tested pharmacological manipulation with epinephrine to restore functional transport of P-GUS across the adult BBB. Epinephrine (40 nmol) coinjected i.v. with 131 I-P-GUS induced the transport across the BBB in 8-week-old mice. The brain influx rate of 131 I-P-GUS (0.29 l/g per min) returned to the level seen in neonates. Capillary depletion showed that 49% of the 131 I-P-GUS in brain was in brain parenchyma. No increases of influx rate or the vascular space for 125 I-albumin, a vascular marker, was observed with epinephrine (40 nmol), showing that enhanced passage was not caused by disruption of the BBB. Brain uptake of 131 I-P-GUS was significantly inhibited by M6P in a dose-dependent manner, whereas epinephrine failed to increase brain uptake of nonphosphorylated GUS. Thus, the effect of epinephrine on the transport of 131 I-P-GUS was ligand specific. These results indicate that epinephrine restores the M6P receptor-mediated functional transport of 131 I-P-GUS across the BBB in adults to levels seen in the neonate.
M
ucopolysaccharidosis type VII (MPS VII) is characterized by abnormal lysosomal storage of glycosaminoglycans (GAGs) in most tissues including the CNS. MPS VII is caused by an inherited deficiency of ␤-glucuronidase (␤-D-glucuronoside glucuronosohydrolase; EC 3.2.1.31) (GUS), an enzyme that cleaves glucuronic acid residues from nonreducing termini of GAGs. Enzyme replacement therapy (ERT) with murine or human GUS in MPS VII mice reduces visceral lysosomal storage, normalizes the pathological phenotype, and prolongs lifespan (1) (2) (3) . It also improves abnormal storage in brain if treatment with GUS is begun before 2 weeks of age (2, 4) . Delivering the enzyme to treat CNS storage disease has been a key problem because the blood-brain barrier (BBB) restricts the passage into brain of exogenously administrated enzymes. In a prior study, we found that human phosphorylated GUS (P-GUS) is transported across the neonatal BBB by mannose 6-phosphate (M6P) receptor-mediated transcytosis, and that this transport mechanism is progressively lost with maturation so that, by 7 weeks, mice have little or no transport left (5) . Thus, alterations in the transport of a lysosomal enzyme across the BBB occur with postnatal development, which limits the effectiveness of ERT to adults. Sly et al. (6) and Stahl et al. (7) have demonstrated that the terminal half-life of P-GUS is Ϸ5 min after i.v. injection in MPS VII mice and plasma clearance of P-GUS is predominantly mediated by the mannose receptor in vivo. Saturating the mannose receptor with a high dose of enzyme may improve targeting to M6P receptor-containing tissues. In fact, high-dose ERT in adult MPS VII mice was partially successful in clearing CNS storage (8) . Partial correction of lysosomal storage in brain by high-dose ERT has also been reported in three other murine models of lysosomal storage disease [aspartylglycosaminuria (9) , ␣-mannosidosis (10), and metachromatic leukodystrophy (11) ]. However, ERT to treat CNS storage is still challenging because the BBB restricts the entry of the enzyme to the majority of brain cells.
Several studies have shown that BBB transporters can be modified by pharmacological manipulations. Transport of leptin across the BBB is transiently enhanced by ␣-adrenergic agents in vivo without affecting the integrity of the BBB (12) . It has also been reported that ␣-and ␤-adrenoceptors mediate changes in the permeability in bovine brain microvessel endothelial cells, an in vitro model of the BBB. Both ␣-and ␤-adrenoreceptormediated changes in permeability are abolished by inhibiting fluid-phase pinocytosis (13, 14) .
If the transport mechanism across the BBB for a lysosomal enzyme, which is operative in neonates, could be restored, lysosomal enzymes containing the M6P moiety might be delivered into the brain at therapeutically effective levels, in which case CNS storage diseases could be treated. Here, we report the restoration of M6P receptor-mediated transport of the lysosomal enzyme GUS at the adult BBB by pharmacological manipulation with epinephrine.
Results
Brain Influx of 131 I-P-GUS from Serum After i.v. Injection. The concentration-time profile of 131 I-P-GUS and 125 I-albumin in the serum fraction up to 10 min after the i.v. injection is shown in Fig.  1 . The serum concentration of 131 I-P-GUS declined with time after i.v. injection in 8-week-old mice, as expected from previously demonstrated mannose-and M6P receptor-mediated clearance systems (15, 16) . In contrast, the levels of 125 I-albumin in serum were sustained throughout the experiment. Epinephrine at the doses of 12, 40, and 120 nmol per mouse slightly increased the serum levels of 131 I-P-GUS, and the levels of 125 I-albumin remained unchanged, regardless of the dose. The effects of epinephrine on the entry of 131 I-P-GUS and 125 I-albumin into brain were also examined (Fig. 2) . The coinjection of epinephrine produced a rapid increase in the 131 I-P-GUS taken up by the brain, as calculated from Eq. 3, in a dose-dependent manner. The maximal effects were observed 5 min after the injection. In contrast, in the absence of coinjected epinephrine, the control group showed negligible uptake of 131 I-P-GUS into the brain during the course of the experiment. Thus, adult mice show an epinephrine-induced uptake of P-GUS in the brain, even though the rate of clearance from serum was not detectably affected by epinephrine. At the highest dose of epinephrine, the uptake of 125 I-albumin also showed a significant increase 5 min after the injection, although a smaller increase than that seen for P-GUS. Fig. 3 A and D shows the multiple-time regression analysis of brain/serum ratios for 131 I-P-GUS and 125 I-albumin, respectively. The epinephrineinduced increase in the transport seen for 131 I-P-GUS was not seen for the coinjected 125 I-albumin, indicating the effect was ligand specific. Whereas the slopes of 131 I-P-GUS significantly differed at the various doses from each other [F(3,8) ϭ 12.623; P ϭ 0.00211], the slope in the control group did not significantly deviate from zero [F(1,2) ϭ 2.958; P ϭ 0.2276], suggesting there is no significant influx of P-GUS without epinephrine. Fig. 3 B and E compares the dose-response for epinephrine on the influx rate of 131 I-P-GUS and 125 I-albumin, respectively. 131 I-P-GUS, but not 125 I-albumin, influx was significantly enhanced by 40 and 120 nmol of epinephrine per mouse. The influx rates of 131 I-P-GUS in control and epinephrine (12, 40 , and 120 nmol)-treated groups were 0.06 Ϯ 0.03 (control), 0.13 Ϯ 0.05 (12 nmol), 0.29 Ϯ 0.07 (40 nmol; P Ͻ 0.05), and 0.47 Ϯ 0.05 (120 nmol; P Ͻ 0.001) l/g per min, respectively. Fig. 3 C and F shows the initial volumes of distribution for 131 I-P-GUS and 125 I-albumin, which were unchanged by epinephrine. From these results, the epinephrine-induced transport into adult brain is shown to be ligand-specific and not related to vascular leakage, BBB disruption, or expansion of the brain's vascular space.
Blood-to-Brain Unidirectional Influx Rate (K in ).
Evidence that P-GUS Is Transported into Brain Parenchyma. To determine the extent to which the brain capillaries comprising the BBB retained 131 I-P-GUS rather than transporting it completely across the capillary wall and into brain parenchyma, a capillary depletion study was conducted 10 min after i.v. coinjection of 131 I-P-GUS and 125 I-albumin with or without injection of epinephrine at the dose of 40 nmol per mouse (Fig. 4) . In the absence of coinjected epinephrine, the tissue/serum ratio of 131 I-P-GUS was below the level of detection in both the parenchyma and capillary fractions when compared with the distribution of 125 I-albumin. With coinjection of epinephrine, 131 I-P-GUS was detectable in both the parenchymal fraction (1.04 Ϯ 0.60 l/g) and the capillary fraction (1.08 Ϯ 0.34 l/g). Thus, 49.1% of the 131 I-P-GUS taken up by brain had actually entered the brain parenchyma by 10 min after the treatment with epinephrine, and 50.9% remained in the capillary fraction 10 min after the injection. These results suggest that epinephrine induces transcytosis across the BBB in the adult as has been demonstrated in neonates without epinephrine treatment (5) .
In earlier work, we demonstrated by HPLC that P-GUS found in the parenchymal fraction of brain after infusing the neonate was intact enzyme with 87% of the radioactivity still in a high molecular weight form. To confirm transport of the intact P-GUS in adults in the present study, we infused 10 mg/kg of nonradioactive P-GUS into adult, GUS-deficient MPS VII mice with or without coinjected epinephrine (40 nmol) and measured the activity in whole brain from perfused animals 24 h after injection. Control, noninjected mice had 0.1 Ϯ 0.03 units/ng of activity. Those infused with P-GUS without epinephrine had 1.15 Ϯ 0.36 units/ng activity. Those receiving P-GUS ϩ 40 nmol epinephrine had 2.09 Ϯ 0.34 units/ng activity. Epinephrine enhanced uptake of P-GUS activity into the brain by 78%, in this experiment, and the catalytic activity of the enzyme indicates the P-GUS entered as intact enzyme.
Specificity of 131 I-P-GUS Uptake by Brain and Peripheral Tissues.
To determine whether the epinephrine-induced transport across the BBB was mediated by the M6P receptor as it is in neonates, we examined the effects of coinjected M6P (0.02-2 mol per mouse) on epinephrine-induced P-GUS delivery to the brain. A dose-dependent inhibition of the epinephrine-induced uptake of 131 I-P-GUS was observed, and 0.2 (P Ͻ 0.001) and 2 mol (P Ͻ 0.001) of coinjected M6P completely inhibited the uptake (Fig.  5A) , suggesting that the epinephrine-induced uptake in the adult brain is mediated by the M6P receptor. A further test of this hypothesis was carried out by the experiment shown in Fig. 5B , which compares the effect of epinephrine on the transport of P-GUS with that of NP-GUS, the nonphosphorylated form of the enzyme; NP-GUS is not transported across the neonatal BBB nor is it a ligand for the M6P receptor. Epinephrine induced uptake only for the M6P-phosphorylated recombinant enzyme.
We next determined whether epinephrine induced uptake by the heart and liver, two other tissues that express the M6P receptor in the neonate, and whether uptake was inhibited by M6P (Fig. 6 ). Fig. 6A shows significant epinephrine-induced uptake by heart (P Ͻ 0.001) and that this uptake was inhibited by M6P in a dose-dependent manner (0.02 mol: P Ͻ 0.05; 0.2 and 2 mol: P Ͻ 0.001). By contrast, epinephrine had no effect on the quantitatively much greater delivery to liver (Fig. 6B) , and inhibition by M6P did not reach statistical significance. In contrast to heart, where most of the delivery is mediated by the M6P receptor, most of the delivery to liver is mediated by the mannose receptor (6, 15), which is not inhibited by M6P.
Discussion
CNS delivery of lysosomal enzymes is a major obstacle to the treatment of lysosomal storage diseases in the adult (2, 5, 8) . The main reason is the inability of the enzyme to penetrate the adult BBB. In our prior study, we demonstrated that saturable transport of P-GUS across the BBB in neonates is mediated by the M6P receptor (5) . As a result, neonates treated with P-GUS have decreases in both CNS and peripheral tissue levels of mucopolysaccharides (2). Unfortunately, M6P receptor transport function declines with development until adults have little or no transport activity (5) . As a result, treatment of adults with conventional doses of P-GUS reduces only peripheral tissue levels of storage. In this study, we found that transport of the enzyme P-GUS across the BBB could be induced in adult mice by treating them with epinephrine and that this transport was attributable to the M6P receptor, the same receptor responsible for P-GUS transport in the neonate.
We found (Ϯ)-epinephrine stimulates brain uptake of P-GUS across the BBB. The percent of the injected dose (ID) of P-GUS entering a gram of brain (%ID/g) was increased in mice treated with epinephrine, and the peak value was observed 5 min after the injection. No significant uptake of P-GUS was observed in controls, suggesting that the levels of epinephrine physiologically present in blood do not affect P-GUS transport.
Multiple-time regression analysis showed that epinephrine increased the unidirectional influx rate of P-GUS in a dosedependent manner. The influx rate of P-GUS into adult brain after epinephrine (40 nmol) treatment was 0.29 l/g per min. This rate is comparable to the rate seen in the neonatal mouse (0.2-0.3 l/g per min), suggesting the transport of P-GUS in the adult BBB was restored by epinephrine to the levels that result in effective ERT in neonates.
In comparison, brain uptake of albumin as measured by the percent of ID per gram of brain was not affected by epinephrine treatment except at the highest dose (120 nmol). The initial volumes of distribution of P-GUS and albumin remained unchanged regardless of the amount of epinephrine. Therefore, epinephrine (12 and 40 nmol) did not alter the vascular space of the brain or disrupt the BBB.
A capillary depletion study revealed that, at 10 min after the coinjection of P-GUS and epinephrine (40 nmol), Ϸ49% of P-GUS taken up by the whole brain reached brain parenchyma and Ϸ51% of the P-GUS was sequestered by brain capillaries. It is unclear whether this P-GUS sequestered by the brain capillaries was permanently trapped by them or whether this represented P-GUS in transit from blood to brain.
The epinephrine-induced uptake of P-GUS in adult mice is mediated through the M6P receptor, as shown in neonates (5) . The brain uptake of P-GUS induced by epinephrine was significantly reduced by the coinjection of M6P in a dose-dependent manner. Epinephrine-induced P-GUS uptake was totally inhibited by M6P at 0.2 and 2 mol, i.e., reduced to the levels of vascular space as measured by albumin. NP-GUS, which does not have the M6P moiety on its sugar chain, did not respond to epinephrine. These results confirm that the uptake process of P-GUS at the BBB was ligand-specific and that epinephrine is a potent stimulator of P-GUS transport mediated by the M6P receptor in adult BBB. We also demonstrated that P-GUS delivered into the brain has enzymatic activity after the coinjection of nonradioactively labeled P-GUS and epinephrine (40 nmol) in MPS VII mice, indicating that the enzyme delivered was intact and biologically active.
Although both ␣-and ␤-adrenoceptors are found in brain microvessel endothelial cells (17) (18) (19) , the exact mechanism by which epinephrine modulates the transport of P-GUS across the adult BBB was not elucidated in this study. Currently, there is no direct evidence that epinephrine modulates the activity of the M6P receptor itself.
Epinephrine is known to modulate endocytotic activity of the BBB, leading to changes in BBB permeability in vivo and in vitro (13, 14) . Although epinephrine may stimulate fluid-phase pinocytosis, this process would be nonspecific and not receptormediated. The enhanced uptake of GUS is clearly M6P-specific. This finding suggests that adrenergic effects of epinephrine modify the transcytotic activity of M6P receptors, which are known to participate in the cellular trafficking of lysosomal enzymes (20, 21) . Intracellular pools of M6P receptors exist in some cell types, including microvascular capillaries, that are available for translocation to the membrane surface in response to hormonal stimuli and phorbol esters (22) (23) (24) (25) (26) . Such redistribution of M6P receptors to the capillary surface in response to 
